dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Gil-Gil, Miguel J. |
dc.contributor.author | Bergamino, Milana |
dc.contributor.author | Barnadas, Agustí |
dc.contributor.author | Manso, Luis |
dc.contributor.author | Bellet Ezquerra, Meritxell |
dc.contributor.author | Saura Manich, Cristina |
dc.contributor.author | Morales, Serafin |
dc.date.accessioned | 2022-02-01T13:37:58Z |
dc.date.available | 2022-02-01T13:37:58Z |
dc.date.issued | 2021-07 |
dc.identifier.citation | Gil-Gil MJ, Bellet M, Bergamino M, Morales S, Barnadas A, Manso L, et al. Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Front Oncol. 2021 Jul;11:645026. |
dc.identifier.issn | 2234-943X |
dc.identifier.uri | https://hdl.handle.net/11351/6949 |
dc.description | Cardiotoxicitat; Doxorubicina liposomal pegilada; Supervivència |
dc.description.sponsorship | The rest of the study was supported by the collaborative group SOLTI. |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Oncology;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Quimioteràpia |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Persones grans |
dc.subject.mesh | Neoadjuvant Therapy |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Progression-Free Survival |
dc.title | Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fonc.2021.645026 |
dc.subject.decs | tratamiento neoadyuvante |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | supervivencia libre de progresión |
dc.relation.publishversion | https://doi.org/10.3389/fonc.2021.645026 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Gil-Gil MJ, Bergamino M] Department of Medical Oncology, Institut Català d’Oncologia, IDIBELL, L’Hospitalet, Spain. [Bellet M, Saura C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Morales S] Department of Medical Oncology, Hospital Arnau de Vilanova, Lleida, Spain. [Barnadas A] Department of Medical Oncology, Hospital de Sant Pau, Barcelona, Spain. [Manso L] Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain |
dc.identifier.pmid | 34307126 |
dc.identifier.wos | 000677390600001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |